Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Specimen #2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Ellagic Acid, Urolithin and Colonic Microbial Communities Affected by Walnut Consumption

NCT04066816
View directory record Official record
Conditions
Colo-rectal Cancer, Colon Cancer, Diet Habit
Interventions
Walnuts
Other
Lead sponsor
UConn Health
Other
Eligibility
50 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

NCT00622895
View directory record Official record
Conditions
Systemic Scleroderma, Severe Systemic Sclerosis
Interventions
fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)

NCT05658471
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Toxicity, Cardiovascular Risk Factors
Interventions
Standardized Research E-Cigarette (SREC), Over the Counter E-Cigarette (EC), Biological Samples, Smoking-related Questionnaires
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

NCT02720263
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, Matching Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 8, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

NCT07136493
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men

NCT06951009
View directory record Official record
Conditions
Urethritis, Healthy Men Age 18-50 With no Urethral Symptoms
Interventions
Colli-Pee, standard of care 60 mL urine cup, Urinalysis, Sysmex UP-5000
Device · Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resources to Enhance the Adjustment of Children (REACH)

NCT00820001
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Booster Treatment, No-Booster, No intervention, Treatment As Usual
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
2
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 8, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

NCT07226856
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Gemcitabine, Imzokitug, Magnetic Resonance Imaging, Nab-paclitaxel, Nivolumab
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

NCT00428077
View directory record Official record
Conditions
Leukemia
Interventions
bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
Biological · Genetic
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 8, 2026, 10:22 AM EDT
Active, not recruiting No phase listed Observational

Hypoglycemia and the Gut Microbiome

NCT03385707
View directory record Official record
Conditions
Hypoglycemia
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

NCT04828551
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
Ultrasound based shear wave speed and fat quantification methods, Blood collection, Physical measurements, Clinical history and medication reviews
Device · Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Diego, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 8, 2026, 10:22 AM EDT
Completed No phase listed Observational

Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study

NCT01365975
View directory record Official record
Conditions
Pediatric Leukemia, Other Pediatric Cancers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 60 Years
Enrollment
1,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff

NCT04899245
View directory record Official record
Conditions
Children With Medical Complexity (CMC), COVID-19
Interventions
BinaxNOW Rapid Antigen System
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT01670877
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Neratinib, Fulvestrant, Trastuzumab, Tumor biopsy, Research blood sample
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 8, 2026, 10:22 AM EDT
Not yet recruiting Not applicable Interventional

Synovial Fluid Withdrawal or PRP Injection For Acute ACL Tears and Cytokines

NCT07142369
View directory record Official record
Conditions
Posttraumatic Osteoarthritis, Anterior Cruciate Ligament (ACL) Rupture
Interventions
Synovial Fluid withdrawal at the preoperative clinic visit, Platelet-Rich Plasma (PRP) preparation and injection, Synovial fluid withdrawal at the time of surgery, 3mL synovial fluid withdrawn at the preoperative visit
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

NCT03150693
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 39 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

NCT05554406
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin and Learning for Teaching

NCT02393443
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 30 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

NCT00514215
View directory record Official record
Conditions
Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
Biological · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 8, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05633615
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel
Biological · Procedure · Drug + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
87
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 8, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Depression, Cytokines and Pancreatic Cancer

NCT00582699
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
assessment interview and blood draw
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 8, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06757647
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging of the Heart
Drug · Procedure
Lead sponsor
Seema Bhat
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 8, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

NCT02341274
View directory record Official record
Conditions
Bioequivalence
Interventions
Tacrolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 8, 2026, 10:22 AM EDT